SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r IN Race/Gender HIV+ Patients Randomized to Therapeutic Drug Monitoring or Standard of Care

TerminadoFase 3ClinicalTrials.gov

ID: NCT00440271Tipo: INTERVENTIONALInicio: 1 de feb de 2007

Traducción no disponible, mostrando original

Resumen

The primary purpose of this study is to: 1. Demonstrate the safety and efficacy of tipranavir/ritonavir (TPV/r) among a racially diverse HIV+ population (males and females) who are three-class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) experienced with documented resistance to more than one PI. 2. Determine pharmacokinetic data in this racially and gender diverse population. 3. Determine the potential utility of using therapeutic drug monitoring (TDM) in improving efficacy outcomes.

Elegibilidad

Edad mínima: 18 YearsSexo: ALL

Criterios de inclusión

HIV-1 infected adults, men and women at least 18 years of age.
class (nucleoside reverse transcriptase inhibitor (NRTI), non-nucleoside reverse transcriptase inhibitor (NNRTI), and protease inhibitor (PI)) treatment-experienced (min of 3-months duration for each class) with resistance to more than one PI (on screening resistance testing). NNRTI-naïve patients who have genotypically documented NNRTI-resistance mutations on past or screening resistance testing would be eligible.
CD4+ T lymphocyte count \>=50 cells/mm3.
HIV-1 viral load \>=1,000 copies/mL at screening.
The antiretroviral (ARV) study treatment regimen must consist of TPV/r in combo with an optimized background regimen (OBR) of 2-4 agents: N(t)RTIs (NRTI or NtRTI), enfuvirtide (ENF), and/or, where available, a trial approved expanded access program (EAP) investigational agent.
Acceptable screening laboratory values that indicate adequate baseline organ function.
Acceptable medical history with a chest X-ray without evidence of active disease and an electrocardiogram (ECG) without clinically important abnormalities within one year of the study.
A reliable method of barrier contraception will be used by all female patients who are of childbearing potential.

Criterios de exclusión

Known hypersensitivity to the tipranavir (TPV) or ritonavir (RTV).
ARV medication naïve.
Genotypic resistance to TPV (defined as a TPV mutation score \>7).
Patients on recent drug holiday, defined as off antiretroviral (ARV) medications for at least 7 consecutive days within the month prior to screening.
Prior tipranavir use.
Inability to adhere to the requirements of the protocol.
Patients with prior history of hemorrhagic stroke or intracranial aneurysm.
Patients with a history of ischemic stroke, neurosurgery or skull trauma within 4 weeks prior to screening.
History of Progressive Multifocal Leukoencephalopathy, Visceral Kaposi's Sarcoma, and/or any malignancy.
Any acquired immunodeficiency syndrome (AIDS) defining illness that is unresolved, symptomatic or not stable on treatment for at least 12 weeks at screening visit.

Intervenciones

drug

tipranavir

drug

ritonavir

drug

Optimized Background Regimen (OBR)

Patients received between two and four active anti-retroviral medications based on resistance testing results, as background treatment, and remained on these for the duration of the trial.

Ubicaciones

1182.98.5405 CENTRO de INFECTOLOGIA y ASISTENCIA (CIAS)

Capital Federal ,Buenos Aires, Argentina

1182.98.5403 Centro Hospital Higa - Dr Oscar Alende

Mar del Plata, Argentina

1182.98.5402 Caici

Rosario, Argentina

Patrocinadores

PrincipalBoehringer Ingelheim

Aviso: La información de este ensayo proviene de fuentes públicas y tiene carácter exclusivamente informativo. No constituye asesoramiento médico, regulatorio ni de ningún otro tipo. Las traducciones son automatizadas y no poseen validez oficial. Consultá siempre con un profesional de la salud. Ver Términos de Uso.

SPRING: Safety, Efficacy, Pharmacokinetics of tipRanavi/r... | EligiMed